caa a22 4500 465785352 CHVBK 20180323112007.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00812364 doi (NATIONALLICENCE)springer-10.1007/BF00812364 Evaluation of technetium 99m cyclobutylpropylene amine oxime as a potential brain perfusion imaging agent for SPET [Elektronische Daten] [Lucia Bacciottini, Fabio Lunghi, Alberto Pupi, Chiara Bonino, Andreas Formiconi, Maria De Cristofaro, Anna Petti, Ugo Meldolesi] Technetium 99md,l-cyclobutylpropylene amine oxime (99mTc-CBPAO) has been developed as a brain-imaging agent for single photon emission tomography (SPET).99mTc-CBPAO can be prepared using a simple labelling procedure suitable for routine clinical use. It has a high in vitro stability, as has been demonstrated by high-pressure liquid chromatography (HPLC) analysis. This shows that 3 h after labelling, less than 5% of the primary lipophilic complex which is capable of crossing the blood-brain barrier (BBB) converts to a secondary hydrophilic complex. Brain uptake (% dose/g wet tissue) of99mTc-CBPAO, determined at 5 and 30 min after injection in two groups of six adult male Sprague-Dawley rats, was found to be 0.74±0.06 and 0.73±0.13 (mean ± SD), respectively. These values are not significantly different from those obtained repeating the experiment with99mTc-labelled hexamethylpropylene amine oxime (99mTc-HMPAO) (0.72±0.15 at 5 min and 0.88 ± 0.24 at 30 min after injection). Since the rat brain uptake of99mTc-CBPAO remained unchanged for a period of time suitable for tomographic study, the comparison of the two tracers was extended to two groups of ten patients. The latter were affected by neurological and psychiatric disorders and were studied with SPET. Human brain uptake (% dose/cc cortical grey matter) of99mTc-CBPAO and99mTc-HMPAO were 3.04±0.57 and 4.22±0.46 (mean × 10−3 ± SD × 10−3), respectively, with a 32% significant difference. In two other groups of five patients, the first transit time-activity curves of the two tracers were compared. From the analysis of these curves we suggest that99mTc-CBPAO has a higher binding effect on blood components and/or a higher degradation rate in blood than that of99mTc-HMPAO. This may account for the reduced human brain uptake. In conclusion, SPET images of99mTc-CBPAO reflect blood perfusion, and they have a good diagnostic quality. The main advantage of99mTc-CBPAO is its in vitro stability; however,99mTc-HMPAO is a superior imaging agent. Springer-Verlag, 1990 Technetium 99m cyclobutylpropylene amine oxime nationallicence Cerebral blood flow nationallicence SPET nationallicence Bacciottini Lucia Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut Lunghi Fabio Sorin Biomedica S.p.A., Via Crescentino, I-13040, Saluggia (VC), Italy aut Pupi Alberto Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut Bonino Chiara Sorin Biomedica S.p.A., Via Crescentino, I-13040, Saluggia (VC), Italy aut Formiconi Andreas Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut De Cristofaro Maria Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut Petti Anna Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut Meldolesi Ugo Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut European Journal of Nuclear Medicine Springer-Verlag 17/5(1990-05-01), 242-247 0340-6997 17:5<242 1990 17 259 https://doi.org/10.1007/BF00812364 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00812364 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Bacciottini Lucia Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut NATIONALLICENCE 700 1- Lunghi Fabio Sorin Biomedica S.p.A., Via Crescentino, I-13040, Saluggia (VC), Italy aut NATIONALLICENCE 700 1- Pupi Alberto Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut NATIONALLICENCE 700 1- Bonino Chiara Sorin Biomedica S.p.A., Via Crescentino, I-13040, Saluggia (VC), Italy aut NATIONALLICENCE 700 1- Formiconi Andreas Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut NATIONALLICENCE 700 1- De Cristofaro Maria Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut NATIONALLICENCE 700 1- Petti Anna Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut NATIONALLICENCE 700 1- Meldolesi Ugo Dipartimento di Fisiopatologia Clinica, Sez. Medicina Nucleare, Università di Firenze, Viale Morgagni 85, I-50134, Florence, Italy aut NATIONALLICENCE 773 0- European Journal of Nuclear Medicine Springer-Verlag 17/5(1990-05-01), 242-247 0340-6997 17:5<242 1990 17 259 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer